Sanofi SA (SAN)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

€77.80

Buy

€78.67

arrow-up€0.89 (+1.15%)

Prices updated at 19 Aug 2026, 16:37 CEST
| Prices minimum 15 mins delay
|
Prices in EUR
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immu ...
FTSE EuroFirst 300
arrow-down-0.09%
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
our Investment Fees and Charges.

logo In the news

Sharecast service unavailable

logo Press releases

logo Key dates

Forecast date
Half yearly resultsJul 2027
Annual general meetingApr 2027
Annual reportFeb 2027
Final resultsJan 2027
Previous date
Half yearly resultsJul 2026
Annual general meetingApr 2026
Annual reportFeb 2026
Final resultsJan 2026

logo Company reports

31 Dec 2025
Annual Report doc-arrow-d
30 Jun 2026
Quarterly Report doc-arrow-d


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.